Lifirafenib-BGB-283-DataSheet-生命科学试剂-MedChemExpress_第1页
Lifirafenib-BGB-283-DataSheet-生命科学试剂-MedChemExpress_第2页
Lifirafenib-BGB-283-DataSheet-生命科学试剂-MedChemExpress_第3页
全文预览已结束

下载本文档

版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领

文档简介

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemELifirafenibCat. No.: HY-18957CAS No.: 1446090-77-2Synonyms: BGB-283分式: CHFNO分量: 478.42作靶点: EGFR; Raf作通路: JAK/STAT Signaling; Protein Tyrosine Kinase/RTK;MAPK/ERK Pathway储存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-

2、20C 1 month溶解性数据体外实验 DMSO : 125 mg/mL (261.28 mM)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制备储备液1 mM 2.0902 mL 10.4511 mL 20.9021 mL5 mM 0.4180 mL 2.0902 mL 4.1804 mL10 mM 0.2090 mL 1.0451 mL 2.0902 mL请根据产品在不同溶剂中的溶解度,选择合适的溶剂配制储备液,并请注意储备液的保存式和期限。BIOLOGICAL ACTIV

3、ITY物活性 Lifirafenib (BGB-283)新型效的Raf激酶和EGFR抑制剂,对重 组BRafV600E 和EGFR的IC50值分别为23 和29 nM。IC50 & Target EGFR BRafV600E EGFRL858R/T790M1/2 Master of Small Molecules 您边的抑制剂师www.MedChemE29 nM (IC50) 23 nM (IC50) 495 nM (IC50)体外研究 Lifirafenib (BGB-283) potently inhibits BRafV600E-activated ERK phosphorylation

4、 and cell proliferation. Itdemonstrates selective cytotoxicity and preferentially inhibits proliferation of cancer cells harboringBRafV600E and EGFR mutation/amplification. In BRafV600E colorectal cancer cell lines, Lifirafenib (BGB-283) effectively inhibits the reactivation of EGFR and EGFR-mediate

5、d cell proliferation 1.体内研究 Lifirafenib (BGB-283) treatment leads to dose-dependent tumor growth inhibition accompanied by partial andcomplete tumor regressions in both cell line-derived and primary human colorectal tumor xenografts bearingBRafV600E mutation 1.PROTOCOLCell Assay 1 Melanoma, colon, b

6、reast, and lung cancer cells are left to attach for 16 hours and then treated with a 10-pointdilution series in duplicate. CellTiter-Glo reagent is added in each well. Mixture is mixed on an orbital shakerfor 2 minutes to allow cell lysing, followed by 10 minutes incubation at room temperature to al

7、lowdevelopment and stabilization of luminescent signal. Luminescent signal is measured using PHERAstar FSreader. EC50 values for cell viability are determined 1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Animal Mice: When the average tumor size rea

8、ches 110 to 200 mm3, mice are randomized to treatment groups andAdministration 1 treated twice per day or once daily by oral gavage (p.o.) with vehicle alone or 2.5 to 30 mg/kg of BGB-283.As control, mice are treated with erlotinib (100 mg/kg qd) or cetuximab (40 mg/kg twice weekly). Lifirafenib(BGB

9、-283) and erlotinib are formulated at the desired concentration as a homogenous suspension in 0.5%(w/v) methylcellulose in purified water. Cetuximab is formulated by diluting the injection solution with salinebefore dosing 1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.REFERENCES1. Tang Z, et al. BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated ColorectalCancers. Mol Cancer Ther. 2015 Oct;14(10):2187-97.McePdfHeightCaution: Product has not been fully validated

温馨提示

  • 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
  • 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
  • 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
  • 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
  • 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
  • 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
  • 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。

评论

0/150

提交评论